Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab-SC for Allosensitization in Heart Transplant Candidates
NCT04610320Phase 1Completed
- Start
- Jul 2021
- Primary completion
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daratumumab in Allosensitization. Primary endpoint: Change in Panel of Reactive Antibodies at 12 weeks. Started Jul 2021; status: completed.
02
Drugs
daratumumab
03
Conditions
Allosensitization
Beyond the preview
Go deeper on NCT04610320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04610320.